

Fig. 1 a




Fig. 1 b



Fig. 1: Model of a complete IgG molecule and Fab fragment; C constant, V variable, CDR complementarity determining regions,

10/522596




Fig. 2: Expression cassette of huFab vector. CDR: complementarity determining region; C: constant light or constant heavy domain; FR: framework region; peIB: leader sequence; pIII: phage protein pIII; SD: Shine-Dalgarno sequence; V_H : variable heavy domain; V_L : variable light domain

FIG. 2

BEST AVAILABLE COPY

Fig. 3





Fig. 4
"naive" library



**structure-plexing:
recombination by ...**

 $V_L \times V_H$ shuffling

$$[V_L - V_{HCDR1-2}] \times HCDR3 \approx 10^{14} \pm$$

$$V_L \times \text{plexed } V_H \not\approx 10^{21} \text{ t}$$

$$\Sigma: 7 \times 10^{17}^*$$

5 x10⁹ operative library

BEST AVAILABLE COPY

10/522596

4/20

footnote to figures 3 and 4:

‡ theoretically accessible library size; * real size of unplexed library; § initial complexity of V_H library subsets

For cosmix-plexing@ the first restriction enzyme used must generate non-palindromic extensive-ends.

The resolution sites in FR3 of V_H (site B¹, B², and B³ in Fig. 3 and 4) are for three different restriction enzymes (B¹ = *Spe*I for Kabat subgroup V_H1, B² = *Hind*III for subgroup V_H2; and B³ = *Xho*I for Kabat subgroup V_H3. This and a characteristic overhang following a *Sap*I restriction at site A between hea and light chain enable conservation of the respective functional framework context.

BEST AVAILABLE COPY

5/20




Figure 5

Structure-plexing protocol ensuring high efficiency recombination restricted to within each of the three V_H framework subgroups: In step 1, circular phagemid DNA from the library is cleaved by the type II restriction enzyme SspI, which creates a unique non-palindromic cohesive end, which is unique for each V_H-framework group. Step 2: When these cleavage products are ligated at high DNA concentration, three sets of concatamers are formed, as shown, each containing only members from the same framework group. Step 3: A second cleavage with the framework group-specific restriction enzymes (SspI, HindIII and XhoI) leads to resolution of the recombination products, i.e. monomeric units are formed which on ligation at low DNA concentration (Step 4) form, by ring closure, phagemid vectors, which have the same general structure as the starting plasmids, but in which the V_H CDR3s have been recombined with V_H-(CDR1+2) variants from other clones. All these reactions can be carried out within a "one pot" reaction without purification of any fragments. Furthermore, it should be noted that during recombination the V_H-CDR3 region remains with the same light chain, a feature which we consider important at early stages when working with large numbers of preselected variants, in order to maintain structural schema. If required entire light and heavy chains can be reshuffled after SfiI and AscI cleavage (not shown in the diagram) with or without the formation of concatamers and their resolution. Variants and recombinants illustrated are shown as single representatives of much larger series.

10/522594




Figure 7





Figure 6: Primers used for the first PCR of light and heavy chains.

Figure 7: Primers used for the second PCR of light and heavy chains, introducing the required restriction sites and the VH subgroup-specific SapI sites. SapI was introduced by amplifications using the indicated AscSap-containing sense primers and the non-sense primer 3'vNhe-. The resulting product was used as mega-primer in an amplification with the primer HUISfi+. The product was cloned after SfiI and NheI digestion. Light chain sequences were cloned using SfiI and AscI. Heavy chain fragments were cloned using either NheI and BclI, HindIII, XhoI for 5' fragments, or MluI and BclI, HindIII, XhoI for the 3' fragments.

7/20



footnote:

A: Recombination via structure-plexing as in Fig. 3

B: Selection round(s)

Further naive and/or selected clones (1, 2 and/or 3) can be subjected to another round of structure-plexing

BEST AVAILABLE COPY

Fig. 8

10/522596

Forward and back primer to introduce a restriction site into FR3 of subgroup VH1:

| | R | V | T | M | T | R | D | T | S | I | S | T | A | Y | M | E | L | S | R | L | R | S | D | D | T | A | V | Y | Y | C | A | R |
|---------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| mostly: | AGG | GTC | ACC | ATG | ACC | AGG | GAC | ACG | TCC | ATC | AGC | ACA | GCC | TAC | ATG | GAG | CTG | AGC | AGG | CTG | AGA | TCT | GAC | GAC | ACG | GCC | GTG | TAT | TAC | TGT | GCG | AGF |
| ambig. | CGN | GTN | ACN | ATG | ACN | CGN | GAY | ACN | WSN | ATH | WSN | ACN | GCN | TAY | ATG | GAR | YTN | WSN | CGN | YTN | CGN | WSN | GAY | GAY | ACN | GCN | GTN | TAY | TAY | TCY | GCN | CGN |

ACT AGT

Index

C ACC ATT ACC GCG GAC ACT AGT TTCCTTCT 3'

3' g Tgg TAA Tgg CgC CTg TgA TCA AAggAAGa 5' H1FR3Spe-

H1FR3Spe-

| | R | V | T | M | T | R | D | T | S | I | S | T | A | Y | M | E | L | S | R | L | R | S | D | D | T | A | V | Y | Y | C | A | R |
|---------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| mostly: | AGG | GTC | ACC | ATG | ACC | AGG | GAC | ACG | TCC | ATC | AGC | ACA | GCC | TAC | ATG | GAG | CTG | AGC | AGG | CTG | AGA | TCT | GAC | GAC | ACG | GCC | CTG | TAT | TAC | TGT | GCG | AGA |
| ambig. | CGN | GTN | ACN | ATG | ACN | CGN | GAY | ACN | WSN | ATH | WSN | ACN | GCN | TAY | ATG | GAR | YTN | WSN | CGN | YTN | CGN | WSN | GAY | GAY | ACN | GCN | GTN | TAY | TGY | GCG | CGN | |

Spel

Spots

5' CCAACCA ACT AGT ACR AGC ACA GCC TAC ATG G 3'

FR3H1Spe+

8/20

Fig. 9

BEST AVAILABLE COPY

93/322590

Forward and back primer to introduce a restriction site into FR3 of subgroup VHII:

mostly: CGA GTC ACC ATA TCA GTA GAC AAG TCC TCC CTG AAG CTG AGC TCT GTG ACC GTG ACC GCG GAC ACG GCC GTG TAT TAC TGT GCG AGA R
ambig: CGN GTN ACN ATH WSN GTN GTN GAY AAR WSN AAY CAR TTY WSN YTN AAR YTN WSN WSN GTN ACN GCG GAY ACN GCG GTN TAY TAY TGY GCN CGT
AAG CTT
HindIII
C CAG TTC TCC CTG AAG CTT TTATTTATA 3'
3' 9 GTC AAG Agg gAC TTC gAA AATAATAT 5' H4FR3Hind-

mostly: CGA GTC ACC ATA TCA GTA GAC AAG TCC TCC CTG AAG CTG AAG CTG AGC TCT GTG ACC GTG ACC GCG GAC ACG GCC GTG TAT TAC TGT GCG AGA R
ambig: CGN GTN ACN ATH WSN GTN GTN GAY AAR WSN AAY CAR TTY WSN YTN AAR YTN WSN WSN GTN ACN GCG GAY ACN GCG GTN TAY TAY TGY GCN CGN
AAG CTT
HindIII
5' CCAACCAA AAG CTT AGC TCT GTG ACC GCG GCR 3' FR3H4Hind+

9/20

Fig. 9 continued

BEST AVAILABLE COPY

10/522596

Forward and back primer to introduce a restriction site into FR3 of subgroup VHIII:

mostly: CGA TTC ACC ATC TCC AGA GAC AAC GCC AAG AAC TCA CTG TAT CTG CAA ATG AAC AGC CTG AGA GCC GAG GAC ACG GCT GTG TAT TAC TGT GCG AGT
ambig.: CGN TTY ACN ATH WSN CGN GAY AAY GCN AAR AAY WSN YTN TAY YTN CAR ATG AAY WSN YTN CGN GCN GAR GAY ACN GCN GTN TAY TAY TGY GCN CGT

CT CGA G

XhoI

ggc CGA TTC ACC ATC TCT CGA GTTATTATA 3'

3' CCg gCT AAg Tgg Tag AgA gCT CAATAATAT 5' H3FR3Xho-

mostly: CGA TTC ACC ATC TCC AGA GAC AAC GCC AAG AAC TCA CTG TAT CTG CAA ATG AAC AGC CTG AGA GCC GAG GAC ACG GCT GTG TAT TAC TGT GCG AGT
ambig.: CGN TTY ACN ATH WSN CGN GAY AAY GCN AAR AAY WSN YTN TAY YTN CAR ATG AAY WSN YTN CGN GCN GAR GAY ACN GCN GTN TAY TAY TGY GCN CGN

CT CGA G

XhoI

CCAACCAA TCT CGA GAY AAT KCC AAG AAC WC FR3H3Xho+

10/20

Fig. 9 continued

BEST AVAILABLE COPY

11/20




Fig. 10 a




Fig 10 b

BEST AVAILABLE COPY

12/20

Figure 11:

huFab -pro- selections on hVEGF

Numbers of input and resulting phages and the applied conditions of selection are shown.

| Panning No. | phage from round | beads | blocker | buffer | | phage input | phage output |
|---|------------------|---------|----------------------|---------------------------------|--------------------------------------|-------------------------|---------------------------|
| | | | | incubation | wash / x-times/total time | | |
| 1-pro- | naive library | Carboxy | 100 mM ethano-lamine | 0.001% PBST in 1% fishge-latine | PBST 0.001 % Tween 10x within 35 min | 1x 10 ¹² cfu | 3.8x 10 ⁴ cfu |
| structure plexing [®] : without LC* shuffling: 6.6 x10 ⁸ new variants; with LC shuffling: 3.3 x10 ⁸ new variants | | | | | | | |
| 1-pro- after plexing | from plexing | Carboxy | 100 mM ethano-lamine | 2YT + 0.01 % Tween | PBST 0.05% Tween 12 x within 45 min | 2x 10 ¹¹ cfu | 2.1 x 10 ⁶ cfu |

* LC: light chain

BEST AVAILABLE COPY

13/20

Figure 12:
huFab -pro- selections on hIGF
Numbers of input and resulting phages and the applied conditions of selection are shown.

| Panning No. | phage from round | beads | blocker | buffer | | phage input | phage output |
|---|-------------------|---------|----------------------|---------------------------------|-------------------------------------|-------------------------|--------------------------|
| | | | | incubation | wash / x-times/total time | | |
| 1-pro- | naive library | Carboxy | 100 mM ethano-lamine | 0.001% PBST in 1% fishge-latine | PBST 0.001 % 10x within 35 min | 1x10 ¹² cfu | 7 x 10 ⁴ cfu |
| cosmix-plexing [®] : without LC* shuffling: 3.8 x 10 ⁸ new variants; with LC shuffling: 5.5 x10 ⁷ new variants | | | | | | | |
| 1-pro- after plex- ing | from plex- ing | Carboxy | 100 mM ethano-lamine | 2YT + 0.01 % Tween | PBST 0.05% Tween 12 x within 45 min | 2x 10 ¹¹ cfu | 1.5x 10 ⁷ cfu |

* LC: light chain

BEST AVAILABLE COPY


2004/013328

14/20

FIG. 13a

Selections on:

1st selection
(from ca 10^{12})



structure-plexing®:

new variants

BEST AVAILABLE COPY

15/20

Phage production from new variants




selection round on respective target:
(challenge with 2×10^{11} particles)

hVEGF

hIGF

2.1×10^6 cfu

1.5×10^7 cfu



positives* after

selection, structure

plexing® + selection:

11

11

positives* after 2 rounds

of selection without

structure plexing®:

2

9

From 60 chosen randomly: * Positives = Abs. ≥ 0.500 in phage ELISA and ≥ 5 fold
over background

BEST AVAILABLE COPY

10/522596

16/20

Target: human VEGF

hVEGF phage-ELISA (021031)




Figure 14


BEST AVAILABLE COPY

10/52259

17/20

Figure 15


Target: human insulin-like growth factor



BEST AVAILABLE COPY

Figure 16


Protein production and purification



F_{ab} yield as purified protein = ca. 4.4 mg / l

19/20

Figure 17
Affinity analysis of interaction between
huFab and huVEGF



Affinity constants

$K_D = 120 \text{ nM}$


$R_{\text{max}} = 606 \text{ RU}, \quad X^2 = 9$

Rate Equation: 1:1 langmuir binding

$$\frac{dR}{dt} = k_a \times C \times (R_{\text{max}} - R) - k_d \times R$$

BEST AVAILABLE COPY

Figure 18
Affinity analysis of interaction between the huFab protein and hIGF (immobilised)



Affinity constants

$$K_D = 10 \text{ nM}$$

$$R_{\text{max}} = 207 \text{ RU}, \quad X^2 = 10$$

Rate Equation: 1:1 langmuir binding

$$\frac{dR}{dt} = k_a \times C \times (R_{\text{max}} - R) - k_d \times R$$